Hadean Ventures is a venture capital and private equity firm investing in life science companies in Europe that is headquartered in Oslo, Norway and was founded in 2014. The firm specifically invests in life science companies operating in the Nordic region of Europe. Hadean Ventures also has an office in Stockholm, Sweden.
Hadean Ventures has made 5 investments and 2 lead investments. Notable investments made by the firm include: Pipeline Therapeutics (series B), Themis Bioscience (series D), SAGA Diagnostics (series A), Nisonic (venture round), and AttgeNO (venture round).
On December 18, 2017 Hadean Ventures announced raising $118 million for their Life Sciences Venture Fund.
On July 7, 2019 Hadean Capital I announced raising €71 million for their Hedean Capital I venture capital fund. Ingrid Teigland Akay, a managing parter of Hadean Capital, made the following statements regarding the companies Hadean Capital I venture capital fund:
We are extremely pleased with the strong support from a broad base of highly experienced institutional and private fund investors. This is a vote of confidence in our strategy, focusing on regions of Europe with high potential within life sciences, yet very few specialized venture investors. I believe we are uniquely positioned to leverage this opportunity with an experienced team and a strong presence in the Nordic region.